HBM Biopharma Summit

24th -26th September 2023

Park Hyatt Zurich

Registration
Add to calendar
Google
Default calendar

WELCOME

For more than a decade, HBM hosted yearly summits, providing a meeting platform for industry professionals and investors to exchange views with experts and peers about the latest developments in the biopharma industry.

DRESSCODE

Business casual (casual for dinners) throughout the conference.

NETWORKING

With networking being a key element of the HBM Biopharma Summit, we have enough time reserved for you to interact with other participants.

PARTICIPANTS

Download list of participants

SPEAKERS

Paul Hudson, CEO Sanofi (keynote)

Jeff Berkowitz, Real Endpoints | Kim Blackwell, Zentalis | Leon Chen, 6 Dimensions Capital | Athena Countouriotis, Avenzo Therapeutics | Richard Girling, Centerview Partners | Mark McKenna, Prometheus Biosciences | Melanie Senior, Biopharma reporter for Nature Biotechnology, Evaluate Pharma, IN VIVO | Norman E. Sharpless, formerly National Cancer Institute (NCI) speaking about trends and developments in the biopharma industry.

PRESENTING COMPANIES

Adrenomed | Affimed | Alpha Intelligence Capital | ALX Oncology | Arrakis Therapeutics | Basilea | Biomea Fusion | Dren Bio | eGenesis | IO Biotech | Jianke | Mahzi | MeiraGTx | Mineralys | Neuron23 | NiKang Therapeutics | Norgine | Numab | Odyssey Therapeutics | Sai Life Sciences | Swixx BioPharma | Upstream Bio | Zymeworks

EXPERT PANEL

Melanie Senior, Biopharma Reporter & Science Strategy Writer (moderator)

Interactive dialogue with Kim Blackwell, Athena Countouriotis and Norman E. Sharpless.

CONFERENCE PROGRAM

SPEAKERS

Paul Hudson
CEO Sanofi

Paul Hudson is reshaping Sanofi into a modern healthcare company with the ambition to transform the practice of medicine. Driven by a purpose to chase the miracles of science to improve people’s lives, Paul and the Sanofi teams are focusing efforts to discover, develop and make accessible breakthrough medicines and vaccines for people around the world. Under Paul’s leadership, the company has prioritized social impact by putting diversity, equity and inclusion, as well as health and environmental sustainability, at the core of its long-term strategy. Before joining Sanofi, Paul was CEO of Novartis Pharmaceuticals from 201 6 to 2019, and a member of the Novartis Executive Committee. His career in healthcare has spanned the globe, with assignments in the US, Japan and Europe. Prior to Novartis, he worked for AstraZeneca, where he held several increasingly senior positions and most recently carried out the roles of president, AstraZeneca US and executive vice president, North America. He began his career in sales and marketing roles at GlaxoSmithKline UK and Sanofi-Synthélabo UK. Paul holds a degree in economics from Manchester Metropolitan University in the UK, and in July 2018 his alma mater awarded him an honorary Doctor of Business Administration for his achievements in industry.

Jeff Berkowitz
CEO Real Endpoints

Mr. Berkowitz is one of the rare top executives whose career has spanned most key verticals in global healthcare — with executive committee and other senior roles at United Health Group, Walgreens Boots Alliance (formerly Walgreens), Merck and Schering-Plough. He joined RE from UnitedHealth Group/Optum where he led Optum’s International division as CEO while also driving key strategic initiatives within Optum’s pharmacy benefits management division. Prior to joining United, Mr. Berkowitz served as President of Pharma and Global Market Access at the Walgreens Boots Alliance, responsible for generic and branded procurement, inventory management, relationships with pharmaceutical companies as well as the companies pricing and reimbursement strategies with all payors and payor segments. Mr. Berkowitz also had responsibility for the specialty pharmacy business with over $10 billion in revenue and 5,800 employees. Mr. Berkowitz joined Walgreens from Merck & Co., where, as SVP of global market access, he was accountable for all access, pricing, payer marketing, health outcomes and health technology assessments worldwide. Mr. Berkowitz had held a similar position at Schering-Plough, where he started as legal director for Schering-Plough’s managed care and commercial group in 1998. Before joining Schering, Mr. Berkowitz was a healthcare attorney for the international law firm Proskauer LLP in New York and Washington, D.C. Mr. Berkowitz earned his bachelor’s degree in political science from Union College in Schenectady, N.Y., and his Juris Doctor from Brooklyn Law School in Brooklyn, N.Y. He has been recognized three times in PharmaVoice magazine as one of the 100 Most Inspiring Leaders in the Life Sciences in 2009, 2010 and 2012 and is the recipient of PharmaVoice’s inaugural Red Jacket recognition. Mr. Berkowitz serves on the board of directors of H. Lundbeck A/S, Esperion Therapeutics, Inc., and Zealand Pharmaceuticals, Inc. Berkowitz also serves as an Editorial Advisor to Life Science Leader and Pharmaceutical Commerce magazines and served on the Board of Directors of the Swiss-American Chamber of Commerce.

Kim Blackwell
CEO Zentalis

Kimberly is the Chief Executive Officer at Zentalis Pharmaceuticals. Prior to joining Zentalis, she served as Chief Medical Officer and Senior Vice President, Oncology Clinical Development, at Tempus Labs. In this role, she oversaw precision medicine initiatives to improve cancer care and guide therapeutic drug development and discovery. Prior to joining Tempus, Kim was VP of Early Phase Oncology and Immunology-oncology at Eli Lilly and Company, where she worked on early-stage cancer therapeutics. During her time at Lilly, she was named as one of “Twenty extraordinary women in biopharma R&D who worked their way to the top” by Endpoints News. For 18 years, Kim was a faculty member at the Duke University Cancer Institute. While at Duke, she served as the principal or co-principal investigator for over 50 cancer clinical trials, co-founded the radiotherapeutics company-Cereius, and co-directed the Woman’s Cancer Program and Precision Medicine Initiative. As one of the nation’s leading breast cancer researchers, she played a role in developing therapies that represent revolutionary non-chemotherapy-based approaches for treating cancer. This work led to Kim’s inclusion in TIME Magazine’s 100 Most Influential People in the World for 2013, recognizing her accomplishments contributing to the development of lapatinib and T-DM1 for the treatment of HER2+ breast cancer. She holds a BA degree in Bioethics from Duke University and a MD degree from Mayo Clinic Medical School.

Leon Chen
Founding Partner and CEO 6 Dimensions Capital

Leon Chen is one of the most productive life sciences venture capital investment professionals with extensive experience in China, North America and Europe. With decades of collective cross- border successful investment track records. Dr. Chen is the Chairman and CEO of 120 Capital, a successor fund of 6 Dimensions Capital, and CEO and Founding Managing Partner of 6DC, formed in 2017 through a merger between Frontline BioVentures with WuXi Healthcare Ventures. Prior to that, he founded Frontline BioVentures, a cross-border venture capital firm in 2012. Under Dr. Chen’s leadership 6DC has grown significantly to become one of the top healthcare venture capital institutions with teams on the ground in both the U.S. and China, with over US$1.6 billion assets under management. 6DC currently has an active portfolio of near 100 companies. Dr. Chen has over 30 years of experience in the life sciences industry as a venture capital investor, senior management executive, entrepreneur, and scientific inventor. Dr. Chen is one of the earliest Western-trained healthcare investors established in China, a pioneer of the industry when he led an investment in CITIC Pharmaceutical Co., Ltd. back in 2006. Since then, he has led/co-led investments in many notable companies including Cathay Biotech Inc., Shanghai Hile Bio-Technology Co., Ltd., Innovent Biologics, Inc., Ocumension Therapeutics, Cutia Therapeutics, Hua Medicine, CStone Pharmaceuticals, Adagene (Suzhou) Limited., Yikon Genomics Co. Ltd., TenNor Therapeutics Ltd., Coherent Biopharma (Suzhou) Co., Ltd., GKHT Medical Technology Co., Ltd., SinoHealth (Shanghai) Co. Ltd., Neusoft Medical Systems Co. Ltd., Shenzhen Kangtai Biological Products Co., Grail, Gracell, EngineBio Ltd., and 111.com. Dr. Chen has a distinct track record of identifying unmet needs, creating and seeding startups addressing the unmet needs, building management teams and helping the companies to become unicorns. Some of these landmark investments include: Innovent Biologics, Occumension Theraputics, and Cutia Therapeutics. Dr. Chen conducted post-doctoral research in chemistry at the Massachusetts Institute of Technology. He obtained his Ph.D. in chemistry (with top honor) from the University of Louvain, Belgium. He graduated from Peking University majoring in chemistry in China.

Athena Countouriotis
Co-founder, President, CEO and Chairperson Avenzo Therapeutics

Athena Countouriotis, M.D., is co-founder, President, Chief Executive Officer and Chairperson of Avenzo Therapeutics. She most recently led Turning Point Therapeutics as President and Chief Executive Officer through its IPO in 2019 to its eventual acquisition by Bristol Myers Squibb for $4.1 billion in August 2022. During the time period, she and her team raised more than $1.2 billion across multiple equity financings. With over 20 years of industry experience, Dr. Countouriotis has served as an officer in both public and private companies, led multiple initial public offerings and acquisitions, and guided several development programs to approval in the U.S. and Europe. She previously served as Senior Vice President and Chief Medical Officer for Adverum Biotechnologies and Halozyme Therapeutics. Dr. Countouriotis also served as Chief Medical Officer of Ambit Biosciences, where she helped lead the company’s initial public offering and was responsible for the clinical development of quizartinib until the company’s acquisition by Daiichi Sankyo in November 2014. Earlier in her career, Dr. Countouriotis led various clinical development organizations within Pfizer and Bristol-Myers Squibb for oncology therapeutics including Sutent®, Mylotarg®, Bosulif® and Sprycel®. Dr. Countouriotis also serves on the board of directors of Iovance Biotherapeutics, Passage Bio, Recludix Pharma, Leal Therapeutics and Capstan Therapeutics. She earned a B.S. from the University of California, Los Angeles, and an M.D. from Tufts University School of Medicine. She received her initial medical training in pediatrics at the University of California, Los Angeles, and additional training at the Fred Hutchinson Cancer Research Center in the Pediatric Hematology/Oncology Program.

Richard Girling
Partner, Centerview Partners

Richard Girling is one of Europe’s leading healthcare bankers with over 30 years of experience. Mr. Girling has advised on many of the largest global healthcare transactions including: AstraZeneca in its $39bn acquisition of Alexion and its $15bn acquisition of MedImmune, Sanofi’s $73bn acquisition of Aventis and its $1.9bn acquisition of Kadmon, the $24bn LBO of Alliance Boots plc and its subsequent $27bn sale to Walgreens and Vifor Pharma on its $12bn sale to CSL. Mr. Girling established the European business of Centerview Partners in London in 2009. Since the creation of the Healthcare practice at Centerview Partners, the Healthcare team has advised on a number of significant transactions including: Walgreens Boots Alliance on the $6.5bn sale of its Alliance Healthcare businesses to AmerisourceBergen, Servier on its acquisition of the 49% minority stake in Egis, CSL on its acquisition of Aventis Behring and its acquisition of Novartis’ influenza vaccines business, Hikma on its acquisition of Boehringer Ingelheim’s Roxane Laboratories, Aspen on the sale of its infant nutritionals business, NeuroDerm on its $1.1bn sale to Mitsubishi Tanabe, Galenica on its $2bn IPO of Galenica Santé and separation of Vifor Pharma, Takeda on its acquisition of TiGenix and Arvelle Therapeutics on its $960mm sale to Angelini Pharma. Mr. Girling established Merrill Lynch’s European healthcare practice in 1998, and was Global Co-Head of Healthcare investment banking for the last six of those years. Following the acquisition by Bank of America, he was appointed the head of the merged Europe, Middle East and Asia (EMEA) and Asia-Pacific healthcare practices for the combined organization. Mr. Girling joined Merrill Lynch in 1998 from Salomon Brothers, where he worked from 1989 to 1998 and was head of the European Pharmaceutical and Healthcare team. Mr. Girling is a member of the Development Board, St Anne‘s College, Oxford University and a member of the Executive Advisory Board for the Centre for Personalised Medicine at Oxford University. Mr. Girling holds a B.A. and M.A. degrees in Biochemistry from Oxford University.

Mark McKenna
Former Chairman & CEO Prometheus Biosciences

Mark C. McKenna served as Chairman and Chief Executive Officer of Prometheus Biosciences (Nasdaq: RXDX) from 2019-2023. Prometheus Biosciences was a clinical stage biotechnology company which created the first precision therapeutics for immune-mediated diseases which was acquired by Merck for $10.8B in June of 2023. The acquisition represented the largest M&A takeout of pre-phase 3 company. Mr. McKenna brings more than 20+ years of experience and strategic leadership from the Pharmaceutical, Medical Device, MedTech, Consumer and Diagnostics sectors. While at Prometheus, Mr. McKenna raised more than a $1B in private and public financing, led the top performing biotech IPO of 2021 and top performing biotech stock of 2022 and 2023(prior to transaction close). Early investors of Prometheus earned more than 25X return on capital. Mr. McKenna currently serves as Chief Investment Officer and Managing Director of McKenna Capital Partners, a family office dedicated to investing in breakthrough treatments for debilitating diseases. Prior to Prometheus, Mr. McKenna was a corporate officer of Bausch Health and served as President of the subsidiary Salix Pharmaceuticals. There he revitalized the gastroenterology business with a series of strategic acquisitions and product launches, doubling revenue to exceed $2B while enhancing operating margins. Earlier, Mr. McKenna served at Bausch + Lomb for more than a decade, most recently as SVP and General Manager of the US Vision Care business where he significantly grew revenue by 22% CAGR in an otherwise flat market. He began his career at Johnson & Johnson and held several positions of increasing responsibility. Mr. McKenna holds a degree in Marketing from Arizona State University and a MBA from Azusa Pacific University. Mr. McKenna also completed the Wharton’s Fellows program at the University of Pennsylvania school of business. Mr. McKenna is passionate about solving big problems in medicine and is regularly featured on CNBC’s Mad Money and Bloomberg radio. In addition, Mr. McKenna is a frequent guest speaker at the Longwood Healthcare conference and other industry thought-leader events. In 2023, he was selected as EY’s Entrepreneur of the year, recognizing his contributions to advancement of entrepreneurship and science.

Melanie Senior
Biopharma reporter for Nature Biotechnology, Evaluate Pharma, IN VIVO. Science strategy writer for biopharma firms

Melanie covers the science and business of biopharma for Nature Biotechnology, Evaluate Pharma and Citeline. She also supports selected pharma, biotech and market access firms with news analyses and reports. After beginning her career at the London Financial Times, Melanie became Bureau Chief, Europe, for Elsevier Business Intelligence. She worked as a reimbursement and pricing analyst for Real Endpoints in the US and was part of EY Life Sciences’ thought leadership team between 2014-2017. Melanie holds a First class degree in Natural Sciences (biochemistry) from Cambridge University and has post-graduate qualifications in Sports Physiology & Nutrition (St Mary’s University) and in International Health Technology Assessment (University of Sheffield). She is based in London, UK.


Norman E. Sharpless
Former Director National Cancer Institute (NCI)

Dr. Sharpless is a physician, scientist, entrepreneur and former federal official, serving as Director of the National Cancer Institute from 2017 to 2022, and as Acting Commissioner of the US Food and Drug Administration in 2019. Prior to government, Dr. Sharpless was the Wellcome Distinguished Professor of Medicine and Director of the Lineberger Comprehensive Cancer Center at the University of North Carolina School of Medicine. He founded G1 Therapeutics, which developed the FDA-approved medicine Cosela (Trilaciclib), used to prevent chemotherapy toxicity. He is currently on the boards of G1 Therapeutics, Karius Inc, and Nucleus Radiopharma; and is the co-Founder of Jupiter BioVentures. He is currently the Professor of Medicine, Cancer Policy and Innovation at the University of North Carolina School of Medicine, and is a member of the American Association for Cancer Research Academy, the Association of American Physicians, the American Society for Clinical Investigation, and the National Academy of Medicine.

PRESENTING COMPANIES

These companies will give each a 20 minutes presentation.

Richard Jones, CEO
Adi Hoess, CEO
Antoine Blondeau, Managing Partner
Jason Lettmann, CEO

James Mutamba, CBO
David Veitch. CEO
Thomas Butler, CEO
Nenad Tomasevic, CEO

Mike Curtis, CEO
Mai-Britt Zocca, CEO
Yuming Zoe, CFO
Yael Weiss, CEO

Zandy Forbes, CEO
Jon Congleton, CEO
Nancy Stagliano, CEO
Zhenhai Gao, CEO

Peter Stein, Chairman
David Urech, CEO
Gary D. Glick, CEO
Krishna Kanumuri, CEO

Dezso Martha, COO / Stuart Swanson, Chairman
Samantha Truex, CEO
Kenneth Galbraith, CEO

REGISTRATION

CONFERENCE LOCATION

Park Hyatt Zurich

Beethovenstrasse 21, Zürich
8002 Zürich

https://www.hyatt.com/en-US/hotel/switzerland/park-hyatt-zurich/zurph?src=corp_lclb_gmb_seo_zurph
zurich.park@hyatt.com

Park Hyatt Zurich is perfectly situated between the picturesque Lake Zurich and the famous Old Town. Indulge in the finest elements of the Swiss commitment to serenity, luxury and art. Enjoy culinary delights, first-class service and all that Zurich has to offer, right from your doorstep.

DINNER LOCATION SUNDAY 24.9.2023

Fischer's Fritz

Seestrasse 557, Zürich
8038 Zürich

http://www.fischers-fritz.ch/

Welcome to Zurich’s most beautiful lake shore. Here you’ll find a maritime world of its own. Only ten minutes from the city centre. The restaurant with fresh fish from Lake Zurich. The beach with chic lounge chairs and prompt service. The campsite for holidays away from holidays. The well-stocked shop with local specialties. The fishery with the freshest fish for sale. All this in a wonderful location, only at Fischer’s Fritz in Zurich Wollishofen directly on the lake.

DINNER LOCATION MONDAY 25.9.2023

Zunfthaus zur Zimmerleuten

Limmatquai 40, Zürich
8001 Zürich

https://zunfthaus-zimmerleuten.ch/en/

The Zunfthaus zur Zimmerleuten, a historical house from the middle ages, is located in the middle of the city directly by the Limmat, in a magnificent building steeped with history from the Middle Ages. The central location of the house is ideal – many companies and sights are easily accessible.